UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-40410
ORION BIOTECH OPPORTUNITIES CORP.
(Exact name of registrant as specified in its charter)
One Vanderbilt Avenue, 26th Floor
New York, NY 10017
(212) 303-1650
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant
Class A ordinary shares included as a part of the units
Redeemable warrants included as part of the Units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15-22(b) | ☐ |
Approximate number of holders of record of the Units: 2
Approximate number of holders of record of the Warrants: 1
Approximate number of holders of record of the Class A ordinary shares:1
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Dated: May 11, 2023
| ORION BIOTECH OPPORTUNITIES CORP. | ||
| By: | /s/ Mark Kayal | |
| Name: | Mark Kayal | |
| Title: | Chief Financial Officer | |